NCT00663195View on ClinicalTrials.gov

Effects of Spironolactone on Matrix Metalloproteinases (MMPs) in Heart Failure

PHASE4CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

January 31, 2004

Study Completion Date

December 31, 2005

Conditions
Chronic Stable Heart Failure
Interventions
DRUG

spironolactone + furosemide

spironolactone 25mg/day, 16 weeks and furosemide 20mg/day, 16 weeks

All Listed Sponsors
lead

Tottori University Hospital

OTHER

NCT00663195 - Effects of Spironolactone on Matrix Metalloproteinases (MMPs) in Heart Failure | Biotech Hunter | Biotech Hunter